Company Description
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency.
The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.
The company was incorporated in 2002 and is headquartered in Redwood City, California.
Country | United States |
Founded | 2002 |
IPO Date | Apr 22, 2010 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 174 |
CEO | Dr. Stephen George Dilly MBBS, Ph.D. |
Contact Details
Address: 200 Penobscot Drive Redwood City, California 94063 United States | |
Phone | 650-421-8100 |
Website | codexis.com |
Stock Details
Ticker Symbol | CDXS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001200375 |
CUSIP Number | 192005106 |
ISIN Number | US1920051067 |
Employer ID | 71-0872999 |
SIC Code | 2860 |
Key Executives
Name | Position |
---|---|
Dr. Stephen George Dilly MBBS, Ph.D. | President, Chief Executive Officer and Director |
Kevin Norrett M.B.A., M.S. | Chief Operating Officer |
Margaret Fitzgerald J.D. | Chief Legal and Compliance Officer, General Counsel and Secretary |
Sriram Ryali M.B.A. | Chief Financial Officer |
Carrie McKim | Director of Investor Relations |
Karen Frechou-Armijo | Senior Vice President and Head of Human Resources |
Dr. Stefan Lutz Ph.D. | Senior Vice President of Research |
Robert Sato M.B.A., Ph.D. | Senior Vice President of Pharmaceutical Development, Quality and Regulatory |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 13, 2024 | 8-K | Current Report |
May 14, 2024 | EFFECT | Notice of Effectiveness |
May 14, 2024 | 424B5 | Filing |
May 14, 2024 | 8-K | Current Report |
May 10, 2024 | UPLOAD | Filing |
May 2, 2024 | S-3 | Registration statement under Securities Act of 1933 |
May 2, 2024 | 10-Q | Quarterly Report |
May 2, 2024 | 8-K | Current Report |
Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 25, 2024 | DEF 14A | Other definitive proxy statements |